Imagia Announces the Appointment of Jennifer M. Buechel to its Board of Directors

Montréal, Canada- May18, 2021 Imagia, a digital healthcare company building a data-analytics platform that accelerates the discovery process of innovative healthcare solutions using data generated in real-world settings today announced the appointment of Jennifer M. Buechel to its Board of Directors, effective immediately.
Ms. Buechel brings more than 20 years of experience as a senior life sciences executive in operations, product development, and portfolio management. Throughout her career, Ms. Buechel has built and scaled product operations in both small and large companies and led program and commercial analyses that drove multi-million dollar investment decisions. She has a proven track record of delivering novel products to the market across diverse technologies (software, pharma, biochemicals, diagnostics) in all aspects of the product life cycle, from R&D to operations and post-sales support. Ms. Buechel is a skilled leader delivering growth in uncertain situations and has led operations and supply chain teams in regulated environments.
“We are very pleased to welcome Jenn to the Imagia Board of Directors,” said Geralyn Ochab, CEO of Imagia. “Jenn brings a wealth of experience and expertise in her field and will be a tremendous asset to Imagia as we further our mission of connecting data and clinical insights for precision oncology”.
“Early and accurate cancer detection will have a meaningful impact on a population’s wellness, and it takes a novel approach to detection, along with strong collaborations, to make this a reality,” said Ms. Jennifer Buechel. “I’m delighted to participate in Imagia’s journey to make these technologies accessible.”

About Imagia

Imagia, an artificial intelligence and healthcare company, develops digital medical innovations that aim to improve the health of cancer patients and those with other heavy-burden diseases. Through its collaborative ecosystem, Imagia EVIDENSTM enables hospitals, medical device manufacturers, pharmaceutical companies, and diagnostic companies around the world to access and utilize healthcare data while preserving data privacy. Headquartered in Montreal, Imagia’s mission is to unlock the potential of data across all organizations to achieve collaborative, medical breakthroughs.

Media Contact:

Imagia
Shelley Epstein
Vice President, Corporate and Public Affairs
[email protected] +1 514 451 6343
Imagia.com

Related posts

Bringing a regulated AI medical device to market — the 5 common compliance pitfalls that impede development

Bringing a regulated AI medical device to market — the 5 common compliance pitfalls that impede development

When you consider the wealth of data that exists in healthcare — from imagery to insurance claims to test results to clinical experiments,

...
Read more
The power of Predictive AI-based Biomarkers in accelerating Precision Oncology

The power of Predictive AI-based Biomarkers in accelerating Precision Oncology

Precision medicine aims to offer a patient, or a subgroup of patients, disease treatment and prevention that has been shown to be optimally

...
Read more
Genomics at Imagia :                                  How AI can help unlock the clinical power of genomic data

Genomics at Imagia : How AI can help unlock the clinical power of genomic data

Genomic data has the potential to be clinically useful, but its use today is very limited – this potential has not been realized. Imag

...
Read more